Media, investors, advocacy organizations and others, please contact us here.

Hero Section Background Image

Publications

Access Travere’s peer-reviewed publications.

Long-Term Outcomes in IgA Nephropathy
Publication NephrologyIgAN

Long-Term Outcomes in IgA Nephropathy

Clinical Journal of the American Society of Nephrology – 2023

Data from the UK National Registry of Rare Kidney Diseases (RaDaR) IgA nephropathy cohort highlight poor long-term outcomes for patients. Read more.

View summary

MA-DS-25-0105 | June 2026

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the PARASOL Initiative
Publication NephrologyFSGS

Sparsentan Clinical Trials in Glomerular Diseases: Defining Endpoints and a Path Forward in Light of the PARASOL Initiative

Future Rare Diseases – 2025

This commentary reflects on the DUPLEX trial results and examines the PARASOL initiative in validating proteinuria as a surrogate endpoint in FSGS clinical trials.

View summary

MA-SP-25-0089 | January 2026

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Publication NephrologyFSGS

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Clinical Journal of the American Society of Nephrology – 2025

A post hoc analysis of the Phase 3 DUPLEX trial assessed the antiproteinuric effect of sparsentan compared with irbesartan in patients with genetic-associated FSGS.

View summary

MA-SP-26-0009 | March 2026

All our publications

Filter by:

Year

Year

×

Therapeutic area

Therapeutic area

×

Disease area

Disease area

×

Product

Product

×

Study/Registry

Study/Registry

×

Study type

Study type

×

Resource type

Resource type

×

Filter by:

Year

Year

×

Therapeutic area

Therapeutic area

×

Disease area

Disease area

×

Product

Product

×

Study/Registry

Study/Registry

×

Study type

Study type

×

Resource type

Resource type

×

Results50

Sort by

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS
Publication NephrologyFSGS

Sparsentan Versus Irbesartan in Pediatric Patients With FSGS

Kidney International Reports – 2026

Read more
Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis
Publication NephrologyFSGS

Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis

The American Journal of Managed Care – 2026

Read more
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis
Publication NephrologyFSGS

Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis

The American Journal of Managed Care – 2026

Read more
Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease
Publication Nephrology

Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease

European Medical Journal – 2026

Read more
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Publication NephrologyFSGS

Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial

Clinical Journal of the American Society of Nephrology – 2025

Read more
Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Publication NephrologyFSGSIgAN

Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy

Glomerular Diseases – 2025

Read more

The publications featured on this page have been partially or fully funded by Travere Therapeutics, Inc., unless noted otherwise. For more information, please refer to the publication.

MSL CTA Image

Connect with our MSL team today

Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.

Find your MSL